Fondazione Sternberg Fondazione Sternberg
Radiographic Progression With and Without Prostate-Speci c Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
About Us

Radiographic Progression With and Without Prostate-Speci c Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

Cora Sternberg is the last author on this practice changing study

This study is important because it highlights the need to provide an accurate radiological monitoring, added to PSA tests, during the follow-up of patients with metastatic hormone-sensitive prostate cancer or nonmetastatic castration-resistant prostate cancer receiving enzalutamide treatment.

Read pdf
SAMUEL AND BARBARA STERNBERG ETS FOUNDATION

MORE ARTICLES

22 Dec
About Us

Dr. Cora Sternberg Named Among Best Female Scientists in the World

Excellence in the Cancer Therapeutics Research Program: Cora Sternberg honored in Research.com's 2025 global ranking.

Read more
10 Jul
About Us

Nejm AI: The Use of Artificial Intelligence for Cancer Therapeutic Decision-Making

Artificial intelligence (AI) has the potential to transform cancer therapeutic decision-making by improving diagnostics and personalizing treatments.

Read more
10 Jul
Interviews

IT AI in Oncology: Hype, Evidence, and the Threshold of Clinical Trust | Precision Signals Ep. 1

In the first episode of Precision Signals, a new podcast from the CEO Roundtable on Cancer, Dr. Sean Khozin speaks with Dr. Cora Sternberg and Dr. Olivier Elemento - two leaders at the intersection of clinical trials, precision medicine, and computational biology.

Read more
28 Nov
News

ASCO Daily News: Dr. Cora Sternberg article about prostate cancer

Is There Sufficient Evidence to Intensify Systemic Therapy in Patients With Prostate Cancer Who Have M1 by PSMA-PET but Negative Conventional Imaging?

Read more
06 Oct
Interviews

ESMO 2024: Cora Sternberg video interview

ESMO 2024: Cora Sternberg video interview about her presentation on event-free survival (EFS) as a surrogate endpoint for overall survival in muscle-invasive bladder cancer.

Read more
12 Sep
News

Investigation of novel pharmacological vulnerabilities of 9p21-deleted bladder cancer cells

This project received funding from the European Research Council (ERC) and from the Samuel and Barbara Sternberg Foundation.

Read more
13 Jul
Interviews

UroToday, Commentary by Cora Sternbeg

The INSIDE-PC study provides evidence of the potential of AI systems in medical literature searches on complex clinical questions.

Read more
12 Jul
Interviews

ESMO Congress 2024

ESMO Congress 2024 - European Society for Medical Oncology Barcellona 13-17 Settembre 2024

Read more
27 May
Interviews

Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study

In this video Cora Sternberg talks about efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel by disease, volume and risk in the phase three Arasens study.

Read more
27 May
Interviews

Urothelial Carcinoma: New Developments

In this video Dr. Cora Sternberg discusses new developments in the treatment of urothelial carcinoma.

Read more
02 Jen
Interviews

AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg

In this interview for UroToday dr. Cora Sternberg presents the latest data and ongoing clinical trials in the context of prostate cancer.

Read more
04 Dec
Interviews

The EV-302 Study and the Implications for Metastatic Bladder Cancer Care

Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy.

Read more